AI Insight
Researchers developed TreatmentFormer, a multimodal deep learning framework that predicts rapamycin treatment response in Alzheimer's Disease patients by integrating brain imaging, microbiome profiles, blood biomarkers, and clinical data. Using a combination of Random Forest feature selection, contrastive learning, and transformer architecture, the model achieved 71.25% prediction accuracy on a dataset of 23 participants. Post-analysis identified blood-based and inflammatory biomarkers as key indicators of treatment response.
Why it matters
This approach demonstrates potential for identifying which Alzheimer's patients may respond to rapamycin treatment based on their biological profiles. The framework could enable better patient stratification in clinical trials and inform personalized treatment strategies, though validation in larger cohorts is needed before clinical application.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Alzheimer’s Disease (AD) remains a leading cause of cognitive decline with no known cure, motivating the development of therapies that slow neurodegeneration. Rapamycin, an FDA-approved inhibitor of the mammalian target of rapamycin (mTOR) pathway, has demonstrated promising anti-aging and neuroprotective effects. However, characterizing its treatment effects and identifying the biological factors that contribute to treatment response remain challenging because of complex interactions across multiple biological systems and the limited availability of patient data. In this work, we propose a three-stage multimodal deep learning framework called TreatmentFormer for predicting rapamycin treatment status from heterogeneous biomedical data including both brain imaging data and tabular data (e.g., microbiome profiles, blood-based biomarkers, cerebral blood flow measurements, and clinical variables (e.g., gender, age, and body mass index)). First, a Random Forest-based feature selection module reduces noise in high-dimensional tabular data while preserving representation across modalities. Second, modality-specific encoders map imaging and tabular inputs into a shared latent space via self-supervised contrastive learning, enabling alignment across modalities. Finally, a transformer-based architecture integrates these representations to capture cross-modal interactions and perform treatment classification. Evaluated on a cohort of 23 participants with baseline and post-treatment timepoints, TreatmentFormer achieves an average prediction accuracy of 71.25% across 10 independent test runs. Despite the challenges of small sample size and heterogeneous data, the model demonstrates stable and consistent performance. Post hoc SHAP-based feature analysis further identifies key biomarkers associated with treatment response, particularly within blood-based and inflammatory modalities. These findings demonstrate that combining feature selection with multimodal representation learning provides a promising and robust approach for modeling treatment effects in small-sample biomedical studies. Importantly, this framework may have significant implications for clinical research and medical applications by identifying the biological features and quantitative measurements that drive individual responses to rapamycin. Such insights could facilitate the development of predictive biomarkers, improve patient stratification, and ultimately inform future approaches to AD diagnosis and therapeutic development.